Tonix Pharmaceuticals Presented Poster Of Tonmya For The Management Of Fibromyalgia At The Annual EULAR 2024
Treatment with Tonmya™ (TNX-102 SL, sublingual cyclobenzaprine HCl) in Phase 3 RESILIENT study significantly reduced daily pain and demonstrated broad fibromyalgia symptom improvement, as demonstrated by